【medical-news】【资讯翻译】默克治疗失眠药物Suvorexant最新三期临床数据
发布于 2012-09-15 · 浏览 1609 · IP 辽宁辽宁
这个帖子发布于 12 年零 266 天前，其中的信息可能已发生改变或有所发展。
http://www.drugs.com/clinical_trials/merck-announces-new-phase-iii-data-suvorexant-investigational-insomnia-medicine-14284.html
认领翻译的战友请跟帖注明“认领本文翻译，48小时内未完成，请其他战友认领！
请根据自己专业背景选择认领，如使用翻译软件翻译，被发现者扣分1-2分
请根据自己的专业背景选择相应的资讯认领，经常认领而不能及时提供优质稿件者将被列入黑名单，取消认领资格，请大家注意！
新近参与本次活动的会员请查看： http://news.dxy.cn/bbs/topic/21537141
寻找最近的翻译贴请查看： http://search.dxy.cn/?words=%E8%B5%84%E8%AE%AF%E7%BF%BB%E8%AF%91&bid=116&t=1&c=1&age=7&bid=116&limit=30&o=1
翻译时请参照版规 【版务】科技动态版版规及加分细则（ 2014-02-21 更新）
希望参与动态版其他活动的会员请查看版面右边栏的置顶部分。
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. The new data are from one of the longest, continuously-dosed, placebo-controlled trials of a sleep medication ever conducted. This 12-month study was designed to assess the safety of suvorexant, while also evaluating its longer term efficacy. Merck presented new results from a two-month discontinuation phase that followed the 12-month study at the 21st Congress of the European Sleep Research Society (ESRS).
“The methods used in this study allowed us to understand what happened when patients who had been taking suvorexant every night for a year were immediately switched to placebo, because what happens when patients stop taking a sleep medication is a key concern for both patients and healthcare professionals,” said James K. Walsh, Ph.D., executive director and senior scientist, Sleep Medicine and Research Center, St. Luke's Hospital, and visiting professor, Department of Psychiatry, Stanford University School of Medicine. "We found that the patients who had been taking suvorexant for 12 months and were switched to placebo saw their insomnia return, but clinically meaningful withdrawal symptoms and rebound insomnia did not emerge. We also obtained efficacy data from patients who continued to take suvorexant through 14 months."
Specifically, results from the two-month discontinuation phase showed that, after daily use of a consistent dose of suvorexant for one year, patients who stopped taking the medicine experienced a return of their sleeping difficulties to levels similar to those reported by patients who received placebo over the course of the trial. Patients who continued to receive suvorexant for the additional two months experienced mean improvements in their ability to fall asleep and stay asleep that were consistent with those seen over the first 12 months compared to placebo. Adverse experiences reported in the two-month discontinuation phase were generally consistent with those reported during the 12-month study.
Merck researchers developed suvorexant to target and block orexins, chemical messengers that originate from the hypothalamus (an important sleep center in the brain) and help keep you awake. By blocking the actions of orexins, suvorexant helps facilitate sleep. Merck plans to file a New Drug Application (NDA) for suvorexant with the U.S. Food and Drug Administration (FDA) in 2012. If approved, suvorexant would be the first in a new class of medicines, called orexin receptor antagonists, for use in patients with difficulty falling or staying asleep. Merck anticipates that suvorexant will be evaluated by the Controlled Substance Staff of the FDA.
“Suvorexant represents a new and different approach to treating insomnia, an area of significant unmet need,” said Darryle D. Schoepp, Ph.D., senior vice president and head of Neuroscience and Ophthalmology franchise, Merck Research Laboratories. “We are enthusiastic about the results of this long-term study, which provide important insights into suvorexant and the chronic nature of insomnia. Merck is continuing with plans to seek approval for suvorexant in the U.S. and in other countries around the world.”
认领翻译的战友请跟帖注明“认领本文翻译，48小时内未完成，请其他战友认领！
请根据自己专业背景选择认领，如使用翻译软件翻译，被发现者扣分1-2分
请根据自己的专业背景选择相应的资讯认领，经常认领而不能及时提供优质稿件者将被列入黑名单，取消认领资格，请大家注意！
新近参与本次活动的会员请查看： http://news.dxy.cn/bbs/topic/21537141
寻找最近的翻译贴请查看： http://search.dxy.cn/?words=%E8%B5%84%E8%AE%AF%E7%BF%BB%E8%AF%91&bid=116&t=1&c=1&age=7&bid=116&limit=30&o=1
翻译时请参照版规 【版务】科技动态版版规及加分细则（ 2014-02-21 更新）
希望参与动态版其他活动的会员请查看版面右边栏的置顶部分。
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. The new data are from one of the longest, continuously-dosed, placebo-controlled trials of a sleep medication ever conducted. This 12-month study was designed to assess the safety of suvorexant, while also evaluating its longer term efficacy. Merck presented new results from a two-month discontinuation phase that followed the 12-month study at the 21st Congress of the European Sleep Research Society (ESRS).
“The methods used in this study allowed us to understand what happened when patients who had been taking suvorexant every night for a year were immediately switched to placebo, because what happens when patients stop taking a sleep medication is a key concern for both patients and healthcare professionals,” said James K. Walsh, Ph.D., executive director and senior scientist, Sleep Medicine and Research Center, St. Luke's Hospital, and visiting professor, Department of Psychiatry, Stanford University School of Medicine. "We found that the patients who had been taking suvorexant for 12 months and were switched to placebo saw their insomnia return, but clinically meaningful withdrawal symptoms and rebound insomnia did not emerge. We also obtained efficacy data from patients who continued to take suvorexant through 14 months."
Specifically, results from the two-month discontinuation phase showed that, after daily use of a consistent dose of suvorexant for one year, patients who stopped taking the medicine experienced a return of their sleeping difficulties to levels similar to those reported by patients who received placebo over the course of the trial. Patients who continued to receive suvorexant for the additional two months experienced mean improvements in their ability to fall asleep and stay asleep that were consistent with those seen over the first 12 months compared to placebo. Adverse experiences reported in the two-month discontinuation phase were generally consistent with those reported during the 12-month study.
Merck researchers developed suvorexant to target and block orexins, chemical messengers that originate from the hypothalamus (an important sleep center in the brain) and help keep you awake. By blocking the actions of orexins, suvorexant helps facilitate sleep. Merck plans to file a New Drug Application (NDA) for suvorexant with the U.S. Food and Drug Administration (FDA) in 2012. If approved, suvorexant would be the first in a new class of medicines, called orexin receptor antagonists, for use in patients with difficulty falling or staying asleep. Merck anticipates that suvorexant will be evaluated by the Controlled Substance Staff of the FDA.
“Suvorexant represents a new and different approach to treating insomnia, an area of significant unmet need,” said Darryle D. Schoepp, Ph.D., senior vice president and head of Neuroscience and Ophthalmology franchise, Merck Research Laboratories. “We are enthusiastic about the results of this long-term study, which provide important insights into suvorexant and the chronic nature of insomnia. Merck is continuing with plans to seek approval for suvorexant in the U.S. and in other countries around the world.”
最后编辑于 2022-10-09 · 浏览 1609
10 收藏点赞
